127 related articles for article (PubMed ID: 37209373)
1. Cholesterol Metabolism Modulation Nanoplatform Improves Photo-Immunotherapeutic Effect in Oral Squamous Cell Carcinoma.
Zhang X; Cao Z; Song C; Wei Z; Zhou M; Chen S; Ran J; Zhang H; Zou H; Han S; Cai Y; Han W
Adv Healthc Mater; 2023 Sep; 12(22):e2300018. PubMed ID: 37209373
[TBL] [Abstract][Full Text] [Related]
2. Near-infrared-II Ag
Xiong H; Shao S; Yang Y; Wang W; Xiong H; Han Y; Wang Z; Hu X; Zeng L; Yang Z; Su T
Biomed Pharmacother; 2024 Jan; 170():116011. PubMed ID: 38157644
[TBL] [Abstract][Full Text] [Related]
3. Ru(II)-modified TiO
Zhou JY; Wang WJ; Zhang CY; Ling YY; Hong XJ; Su Q; Li WG; Mao ZW; Cheng B; Tan CP; Wu T
Biomaterials; 2022 Oct; 289():121757. PubMed ID: 36058028
[TBL] [Abstract][Full Text] [Related]
4. A Bacterial Nanomedicine Combines Photodynamic-Immunotherapy and Chemotherapy for Enhanced Treatment of Oral Squamous Cell Carcinoma.
Shi E; Shan T; Wang H; Mao L; Liang Y; Cao M; Wu Q; Li C; Wang Y; Wang Y
Small; 2023 Dec; 19(52):e2304014. PubMed ID: 37653616
[TBL] [Abstract][Full Text] [Related]
5. Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
Liu J; Zhao J; Qiao X
Endocrinology; 2023 Sep; 164(11):. PubMed ID: 37738154
[TBL] [Abstract][Full Text] [Related]
6. A Spatial Transcriptome Reveals Changes in Tumor and Tumor Microenvironment in Oral Cancer with Acquired Resistance to Immunotherapy.
Iwasa YI; Nakajima T; Hori K; Yokota Y; Kitoh R; Uehara T; Takumi Y
Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136558
[TBL] [Abstract][Full Text] [Related]
7. Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis.
Zi M; Xingyu C; Yang C; Xiaodong S; Shixian L; Shicheng W
Apoptosis; 2023 Apr; 28(3-4):348-361. PubMed ID: 36370260
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment-activatable nanocatalysts with chemodynamic therapy and enhanced autophagy for specific treatment of oral squamous cell carcinoma.
Xu H; Zheng C; Zhang Z; Huang X
Colloids Surf B Biointerfaces; 2024 Apr; 236():113713. PubMed ID: 38422665
[TBL] [Abstract][Full Text] [Related]
9. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
[TBL] [Abstract][Full Text] [Related]
10. A Novel Immune-Related Gene Signature to Identify the Tumor Microenvironment and Prognose Disease Among Patients With Oral Squamous Cell Carcinoma Patients Using ssGSEA: A Bioinformatics and Biological Validation Study.
Chen Y; Feng Y; Yan F; Zhao Y; Zhao H; Guo Y
Front Immunol; 2022; 13():922195. PubMed ID: 35935989
[TBL] [Abstract][Full Text] [Related]
11. Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway.
Li R; Zhou Y; Zhang M; Xie R; Duan N; Liu H; Qin Y; Ma J; Li Z; Ye P; Wang W; Wang X
Int Immunopharmacol; 2023 May; 118():110094. PubMed ID: 37030119
[TBL] [Abstract][Full Text] [Related]
12. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between cancer and different cancer stroma subtypes promotes the infiltration of tumor‑associated macrophages into the tumor microenvironment of oral squamous cell carcinoma.
Shan Q; Takabatake K; Kawai H; Oo MW; Sukegawa S; Fujii M; Nakano K; Nagatsuka H
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35514301
[TBL] [Abstract][Full Text] [Related]
15. Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma.
Ramalingam S; Shantha S; Muralitharan S; Sudhakar U; Thamizhchelvan H; Parvathi VD
Med Oncol; 2023 Sep; 40(10):303. PubMed ID: 37731058
[TBL] [Abstract][Full Text] [Related]
16. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
Zhu C; Li J; Yao M; Fang C
BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
[TBL] [Abstract][Full Text] [Related]
17. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
18. Transcutaneous carbon dioxide application suppresses the expression of cancer-associated fibroblasts markers in oral squamous cell carcinoma xenograft mouse model.
Tadokoro Y; Takeda D; Murakami A; Yatagai N; Saito I; Arimoto S; Kakei Y; Akashi M; Hasegawa T
PLoS One; 2023; 18(8):e0290357. PubMed ID: 37594996
[TBL] [Abstract][Full Text] [Related]
19. Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma.
Wang Z; Zhang H; Zhai Y; Li F; Shi X; Ying M
Front Immunol; 2022; 13():843322. PubMed ID: 35401551
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of gambogic acid to improve anti-tumor immunity against oral squamous cell carcinoma.
Chen X; Chen DR; Liu H; Yang L; Zhang Y; Bu LL; Sun ZJ; Cai L
J Control Release; 2022 Nov; 351():381-393. PubMed ID: 36096364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
